POSSIBILITIES OF GLYCOGEN SYNTHASE KINASE-3Β LEVEL USE AS A BIOMARKER OF THE COMBINED PRECONDITIONING IN THE ISCHEMIC BRAIN


  • O.S. Levchenkova Smolensk State Medical University, Russia
  • Yu.S. Korneva Smolensk State Medical University, Russia
  • V.E. Novikov Smolensk State Medical University, Russia
  • A.E. Dorosevich Smolensk State Medical University, Russia
Keywords: glycogen synthase kinase-3β (GSK-3β), preconditioning, cerebral ischemia, amtizol.

Abstract

POSSIBILITIES OF GLYCOGEN SYNTHASE KINASE-3Β LEVEL USE AS A BIOMARKER OF THE COMBINED PRECONDITIONING IN THE ISCHEMIC BRAIN

References

1. Esposito E., Desai R., Ji X. et al. Pharmacologic pre- and postconditioning for stroke: basic mechanisms and translational opportunity // Brain Circ. 2015; 1(1): 104-113. doi: 10.4103/2394-8108.166380

2. Levchenkova O.S. et al. Influence of combined pharmacological and hypoxic preconditioning on animal survival and functional activity of CNS during model cerebral ischemia // Exp Clin Pharmacol. 2016; 79(6): 3-8. doi: 10.30906/0869- 2092-2016-79-6-3-8.

3. Yang K., Chen Z., Gao J.et al. The key roles of GSK-3β in regulating mitochondrial activity // Cell Physiol Biochem. 2017;44:1445-1459. doi: 10.1159/000485580

4. Huang S., Wang H., Turlova E. et al. GSK-3β inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice // CNS Neurosci Ther. 2017; 23(5): 405-415. doi: 10.1111/cns.12683.
Published
2019-11-07
How to Cite
Levchenkova, O., Korneva, Y., Novikov, V., & Dorosevich, A. (2019). POSSIBILITIES OF GLYCOGEN SYNTHASE KINASE-3Β LEVEL USE AS A BIOMARKER OF THE COMBINED PRECONDITIONING IN THE ISCHEMIC BRAIN. Biological Markers in Fundamental and Clinical Medicine (scientific Journal), 3(1), 63-64. https://doi.org/10.29256/v.03.01.2019.escbm41
Section
Selected abstracts